Image-guided radiofrequency ablation (RFA) is used to treat focal tumors in the liver and other organs. Despite potential advantages over surgery, hepatic RFA can promote local and distant tumor growth by activating pro-tumorigenic growth factor and cytokines. Thus, strategies to identify and suppress pro-oncogenic effects of RFA are urgently required to further improve the therapeutic effect. Here, the proliferative effect of plasma of Hepatocellular carcinoma or colorectal carcinoma patients 90 min post-RFA was tested on HCC cell lines, demonstrating significant cellular proliferation compared to baseline plasma. Multiplex ELISA screening demonstrated increased plasma pro-tumorigenic growth factors and cytokines including the FGF protein family which uniquely and selectively activated HepG2. Primary mouse and immortalized human hepatocytes were then subjected to moderate hyperthermia in-vitro, mimicking thermal stress induced during ablation in the peri-ablational normal tissue. Resultant culture medium induced proliferation of multiple cancer cell lines. Subsequent non-biased protein array revealed that these hepatocytes subjected to moderate hyperthermia also excrete a similar wide spectrum of growth factors. Recombinant FGF-2 activated multiple cell lines. FGFR inhibitor significantly reduced liver tumor load post-RFA in MDR2-KO inflammation-induced HCC mouse model. Thus, Liver RFA can induce tumorigenesis via the FGF signaling pathway, and its inhibition suppresses HCC development.

Department of Radiology and Nuclear Medicine University Hospital Brno and Masaryk University Brno Brno Czech Republic

Department of Radiology University Hospital LMU Munich Munich Germany

Division of Image Guided Therapy and Interventional Oncology Department of Radiology Hadassah Hebrew University Hospital Jerusalem Israel

Laboratory for Minimally Invasive Tumor Therapies Department of Radiology Beth Israel Deaconess Medical Center Harvard Medical School Boston MA USA

The Goldyne Savad Institute of Gene and Cell Therapy Hadassah Hebrew University Hospital Ein Karem Jerusalem Israel

Zobrazit více v PubMed

European Association For The Study Of The Liver EASL clinical practice guidelines: Management of hepatocellular carcinoma. J. Hepatol. 2018;69(1):182–236. PubMed

Meloni MF, et al. Breast cancer liver metastases: US-guided percutaneous radiofrequency ablation—Intermediate and long-term survival rates. Radiology. 2009;253(3):861–869. PubMed PMC

Livraghi T, et al. Hepatocellular carcinoma: Radio-frequency ablation of medium and large lesions. Radiology. 2000;214(3):761–768. PubMed

Nault JC, et al. Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations. J. Hepatol. 2018;68(4):783–797. PubMed

Solbiati L, et al. Small liver colorectal metastases treated with percutaneous radiofrequency ablation: Local response rate and long-term survival with up to 10-year follow-up. Radiology. 2012;265(3):958–968. PubMed

Sotirchos VS, et al. Colorectal cancer liver metastases: Biopsy of the ablation zone and margins can be used to predict oncologic outcome. Radiology. 2016;280(3):949–959. PubMed PMC

Petre EN, Sofocleous C. Thermal ablation in the management of colorectal cancer patients with oligometastatic liver disease. Visc. Med. 2017;33(1):62–68. PubMed PMC

Ahmed M, et al. Hepatic radiofrequency ablation-induced stimulation of distant tumor growth is suppressed by c-Met inhibition. Radiology. 2016;279(1):103–117. PubMed PMC

Velez E, et al. Hepatic thermal ablation: Effect of device and heating parameters on local tissue reactions and distant tumor growth. Radiology. 2016;281(3):782–792. PubMed PMC

Rozenblum N, et al. Oncogenesis: An "Off-Target" effect of radiofrequency ablation. Radiology. 2015;276(2):426–432. PubMed

Markezana A, et al. Moderate hyperthermic heating encountered during thermal ablation increases tumor cell activity. Int. J. Hyperth. 2020;37(1):119–129. PubMed PMC

Erinjeri JP, et al. Image-guided thermal ablation of tumors increases the plasma level of interleukin-6 and interleukin-10. J. Vasc. Interv. Radiol. 2013;24(8):1105–1112. PubMed PMC

Ahmed M, et al. Systemic siRNA nanoparticle-based drugs combined with radiofrequency ablation for cancer therapy. PLoS ONE. 2015;10(7):e0128910. PubMed PMC

Rozenblum N, et al. Radiofrequency ablation: Inflammatory changes in the periablative zone can induce global organ effects, including liver regeneration. Radiology. 2015;276(2):416–425. PubMed

Markezana A, et al. Incomplete thermal ablation of tumors promotes increased tumorigenesis. Int. J. Hyperth. 2021;38(1):263–272. PubMed

Kumar G, et al. Targeting STAT3 to suppress systemic pro-oncogenic effects from hepatic radiofrequency ablation. Radiology. 2018;286(2):524–536. PubMed PMC

Nakagawa H, et al. In vivo immunological antitumor effect of OK-432-stimulated dendritic cell transfer after radiofrequency ablation. Cancer Immunol. Immunother. 2014;63(4):347–356. PubMed PMC

Aly HH, et al. Serum-derived hepatitis C virus infectivity in interferon regulatory factor-7-suppressed human primary hepatocytes. J. Hepatol. 2007;46(1):26–36. PubMed

Yarmolenko PS, et al. Thresholds for thermal damage to normal tissues: An update. Int. J. Hyperth. 2011;27(4):320–343. PubMed PMC

Mertyna P, et al. Radiofrequency ablation: The effect of distance and baseline temperature on thermal dose required for coagulation. Int. J. Hyperth. 2008;24(7):550–559. PubMed

Yang W, et al. Radiofrequency ablation combined with liposomal quercetin to increase tumour destruction by modulation of heat shock protein production in a small animal model. Int. J. Hyperth. 2011;27(6):527–538. PubMed PMC

Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–867. PubMed PMC

Liao H, et al. Thermal ablation induces transitory metastatic growth by means of the STAT3/c-Met molecular pathway in an intrahepatic colorectal cancer mouse model. Radiology. 2020;294(2):464–472. PubMed PMC

Chae YK, et al. Phase II study of AZD4547 in patients with tumors harboring aberrations in the FGFR pathway: Results from the NCI-MATCH trial (EAY131) subprotocol W. J. Clin. Oncol. 2020;38(21):2407–2417. PubMed PMC

Coombes RC, et al. Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer. Nat. Commun. 2022;13(1):3246. PubMed PMC

Katzenellenbogen M, et al. Molecular mechanisms of liver carcinogenesis in the mdr2-knockout mice. Mol. Cancer Res. 2007;5(11):1159–1170. PubMed

Chang Q, et al. The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. Neoplasia. 2013;15(7):848–862. PubMed PMC

Maher JJ. Cell-specific expression of hepatocyte growth factor in liver. Upregulation in sinusoidal endothelial cells after carbon tetrachloride. J. Clin. Investig. 1993;91(5):2244–2252. PubMed PMC

Stanger BZ. Cellular homeostasis and repair in the mammalian liver. Annu. Rev. Physiol. 2015;77:179–200. PubMed PMC

Jondal DE, et al. Heat stress and hepatic laser thermal ablation induce hepatocellular carcinoma growth: Role of PI3K/mTOR/AKT signaling. Radiology. 2018;288(3):730–738. PubMed PMC

Qiu GH, et al. Distinctive pharmacological differences between liver cancer cell lines HepG2 and Hep3B. Cytotechnology. 2015;67(1):1–12. PubMed PMC

Jin-no K, et al. Plasma level of basic fibroblast growth factor increases with progression of chronic liver disease. J. Gastroenterol. 1997;32(1):119–121. PubMed

Li Y, et al. Up-regulation of fibroblast growth factor 19 and its receptor associates with progression from fatty liver to hepatocellular carcinoma. Oncotarget. 2016;7(32):52329–52339. PubMed PMC

Hyeon J, et al. Expression of fibroblast growth factor 19 is associated with recurrence and poor prognosis of hepatocellular carcinoma. Dig. Dis. Sci. 2013;58(7):1916–1922. PubMed

Miura S, et al. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma. BMC Cancer. 2012;12:56. PubMed PMC

Hoshi T, et al. Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK cascades. Biochem. Biophys. Res. Commun. 2019;513(1):1–7. PubMed

Camacho JC, Petre EN, Sofocleous CT. Thermal ablation of metastatic colon cancer to the liver. Semin. Interv. Radiol. 2019;36(4):310–318. PubMed PMC

Thompson SM, et al. Heat stress and thermal ablation induce local expression of nerve growth factor inducible (VGF) in hepatocytes and hepatocellular carcinoma: preclinical and clinical studies. Gene Expr. 2018;19(1):37–47. PubMed PMC

Nijkamp MW, et al. Accelerated perinecrotic outgrowth of colorectal liver metastases following radiofrequency ablation is a hypoxia-driven phenomenon. Ann. Surg. 2009;249(5):814–823. PubMed

Wang JN, et al. Emerging role and therapeutic implication of Wnt signaling pathways in liver fibrosis. Gene. 2018;674:57–69. PubMed

Schumacher JD, Guo GL. Regulation of hepatic stellate cells and fibrogenesis by fibroblast growth factors. Biomed. Res. Int. 2016;2016:8323747. PubMed PMC

Mejhert N, et al. Mapping of the fibroblast growth factors in human white adipose tissue. J. Clin. Endocrinol. Metab. 2010;95(5):2451–2457. PubMed

Thompson SM, et al. Heat stress-induced PI3K/mTORC2-dependent AKT signaling is a central mediator of hepatocellular carcinoma survival to thermal ablation induced heat stress. PLoS ONE. 2016;11(9):e0162634. PubMed PMC

Shady W, et al. Kras mutation is a marker of worse oncologic outcomes after percutaneous radiofrequency ablation of colorectal liver metastases. Oncotarget. 2017;8(39):66117–66127. PubMed PMC

Seitz T, et al. Fibroblast Growth Factor 9 is expressed by activated hepatic stellate cells and promotes progression of hepatocellular carcinoma. Sci. Rep. 2020;10(1):4546. PubMed PMC

Wang Y, et al. FGF/FGFR signaling in hepatocellular carcinoma: From carcinogenesis to recent therapeutic intervention. Cancers (Basel) 2021;13(6):1360. PubMed PMC

Andrasina T, et al. Thermal ablation and transarterial chemoembolization are characterized by changing dynamics of circulating microRNAs. J. Vasc. Interv. Radiol. 2021;32(3):403–411. PubMed

Cohen I, et al. Etk/Bmx regulates proteinase-activated-receptor1 (PAR1) in breast cancer invasion: Signaling partners, hierarchy and physiological significance. PLoS ONE. 2010;5(6):e11135. PubMed PMC

Edrei Y, et al. Vascular profile characterization of liver tumors by magnetic resonance imaging using hemodynamic response imaging in mice. Neoplasia. 2011;13(3):244–253. PubMed PMC

Charni-Natan M, Goldstein I. Protocol for primary mouse hepatocyte isolation. STAR Protoc. 2020;1(2):100086. PubMed PMC

Gavine PR, et al. AZD4547: An orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 2012;72(8):2045–2056. PubMed

Van Haele M, et al. YAP and TAZ heterogeneity in primary liver cancer: An analysis of its prognostic and diagnostic role. Int. J. Mol. Sci. 2019;20(3):638. PubMed PMC

Guilliams M, et al. Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches. Cell. 2022;185(2):379–396.e38. PubMed PMC

Heng TS, Painter MW. The Immunological Genome Project: Networks of gene expression in immune cells. Nat. Immunol. 2008;9(10):1091–1094. PubMed